🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

26 results for “Aldeyra Therapeutics” Clear

  1. ADX-102 1% Topical Dermal Cream (reproxalap)

    Aldeyra Therapeutics

    Sjogren-Larsson Syndrome

    phase 3 small molecule completed

    1 trial

  2. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 3 small molecule completed

    1 trial

  3. ADX-2191 (intravitreal methotrexate 0.8%)

    Aldeyra Therapeutics

    Proliferative Vitreoretinopathy

    phase 3 small molecule completed

    1 trial

  4. ICM ADX-2191 injection

    Aldeyra Therapeutics

    Primary Vitreoretinal Lymphoma

    phase 3 small molecule active

    1 trial

  5. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Allergic Conjunctivitis

    phase 3 small molecule completed

    4 trials

  6. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Disease

    phase 3 small molecule completed

    4 trials

  7. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye

    phase 3 small molecule completed

    4 trials

  8. Reproxalap Ophthalmic Solution (0.25%) QID

    Aldeyra Therapeutics

    Dry Eye

    phase 3 small molecule completed

    1 trial

  9. ADX-102 Ophthalmic Drops (0.5%)

    Aldeyra Therapeutics

    Conjunctivitis, Allergic

    phase 2 small molecule completed

    1 trial

  10. ADX-102 Ophthalmic Solution (0.5%)

    Aldeyra Therapeutics

    Dry Eye Syndromes

    phase 2 small molecule completed

    1 trial

  11. ADX-2191

    Aldeyra Therapeutics

    Retinitis Pigmentosa

    phase 2 small molecule completed

    1 trial

  12. ADX-629

    Aldeyra Therapeutics

    Ethanol Intoxication

    phase 2 small molecule completed

    1 trial

  13. ADX-629

    Aldeyra Therapeutics

    Alcohol Hepatitis

    phase 2 small molecule completed

    1 trial

  14. ADX-629

    Aldeyra Therapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  15. ADX-629

    Aldeyra Therapeutics

    Nephrotic Syndrome

    phase 2 small molecule terminated

    1 trial

  16. ADX-629

    Aldeyra Therapeutics

    Atopic Asthma

    phase 2 small molecule completed

    1 trial

  17. ADX-629

    Aldeyra Therapeutics

    Chronic Cough

    phase 2 small molecule completed

    1 trial

  18. ADX-629

    Aldeyra Therapeutics

    Covid19

    phase 2 small molecule completed

    1 trial

  19. ADX-629 (Open-label)

    Aldeyra Therapeutics

    Atopic Dermatitis

    phase 2 small molecule completed

    1 trial

  20. Active topical NS2 1% dermatologic cream

    Aldeyra Therapeutics

    Sjögren-Larsson Syndrome

    phase 2 small molecule completed

    1 trial

  21. NS2

    Aldeyra Therapeutics

    Non-infectious Anterior Uveitis

    phase 2 small molecule completed

    1 trial

  22. NS2 Ophthalmic Drops (0.5%)

    Aldeyra Therapeutics

    Allergic Conjunctivitis

    phase 2 small molecule completed

    1 trial

  23. Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID

    Aldeyra Therapeutics

    Dry Eye

    phase 2 small molecule completed

    1 trial

  24. Reproxalap Ophthalmic Solution (0.25%)

    Aldeyra Therapeutics

    Dry Eye Syndrome

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources